047920.KQ
HLB Pharmaceutical Co., Ltd
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 7,640.00
+3.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 251.9B | 205.6B | 137.1B | 136.0B | 107.5B |
| Cost of Revenue | 139.2B | 101.4B | 50.5B | 53.0B | 43.8B |
| Gross Profit | 112.8B | 104.2B | 86.6B | 83.0B | 63.7B |
| Operating Expenses | |||||
| R&D Expense | 4.4B | 3.3B | 2.5B | 2.6B | 4.3B |
| SG&A Expense | 104.3B | 93.1B | 74.7B | 92.9B | 61.0B |
| General & Admin Expense | 749.9M | 1.4B | 951.8M | 1.5B | 1.3B |
| Selling & Marketing Expense | 50.8B | 91.6B | 73.8B | 91.4B | 59.7B |
| Other Expenses | 3.4B | 6.7B | 7.8B | 7.0B | 5.3B |
| Total Operating Expenses | 110.9B | 103.1B | 85.1B | 102.5B | 70.6B |
| Cost and Expenses | 250.1B | 204.5B | 135.6B | 155.5B | 114.4B |
| Operating Income (EBIT) | 1.9B | 1.1B | 1.5B | (20.3B) | (6.9B) |
| Non-Operating | |||||
| Interest Income | 588.0M | 654.9M | 429.9M | 403.4M | 298.7M |
| Interest Expense | 730.3M | 738.1M | 621.1M | 11.8B | 5.0B |
| Net Interest Income | (142.3M) | (83.2M) | (191.2M) | (11.4B) | (4.7B) |
| Other Non-Op Income/Expense | 1.1B | 3.9B | (308.3M) | 1.5B | (4.0B) |
| Non-Operating Income (excl Interest) | 4.2M | — | (312.8M) | — | — |
| EBT (Pre-Tax Income) | 3.0B | 5.0B | 1.2B | (18.9B) | (11.0B) |
| Income Tax Expense | 229.7M | 414.0M | (854.1M) | 576.1M | 824.9M |
| Bottom Line | |||||
| Net Income | 2.8B | 4.6B | 2.0B | (19.4B) | (11.8B) |
| Earnings from Cont. Ops | 2.8B | 4.6B | 2.0B | (19.4B) | (11.8B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.8B | 4.6B | 2.0B | (19.4B) | (11.8B) |
| Per Share | |||||
| Basic EPS | ₩84 | ₩141 | ₩64 | (₩666) | (₩431) |
| Diluted EPS | ₩84 | ₩140 | ₩64 | (₩666) | (₩431) |
| Revenue Per Share | ₩7,079 | ₩6,268 | ₩4,325 | ₩4,661 | ₩3,934 |
| Shares | |||||
| Basic Shares Outstanding | 35.6M | 32.8M | 31.7M | 29.2M | 27.3M |
| Diluted Shares Outstanding | 35.6M | 32.8M | 31.7M | 29.2M | 27.3M |
| Profitability Metrics | |||||
| EBITDA | 6.4B | 5.2B | 6.9B | (2.0B) | (1.4B) |
| D&A | 4.5B | 4.1B | 5.1B | 5.0B | 4.5B |
| EBIT | 1.9B | 1.1B | 1.8B | (7.1B) | (5.9B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026